01 / 306 pp
Executive Brief
Meridian Executive Synthesis, SCQA open, 1-sentence governing thought, 3 MECE key lines, each evidence-backed. The single page institutional buyers read first.
MeridianConsensus
Decision-grade Market IntelligenceAny market · any geography
Healthcare
currentUpdated todayNext refresh Jun 15Live · since 5d ago
Boardroom-ready · 8 languages
United States Digital Cognitive Assessment and Digital Therapeutics Market
Valued at $4537.9B in 2025, growing at 5.0% to $7802.3B by 2036.
Request the preview PDF
A 57-page institutional preview of the United States Digital Cognitive Assessment and Digital Therapeutics Market.
What's inside
- Executive brief
- Market sizing · 2020 – Q1 2026 history + 2026–2036 forecast
- Meridian reconciliation vs peer estimates
- Segmentation · product, application, channel, end-user
- 10-region analysis with country-level breakdowns
- Competitive landscape + ranked share + Porter Five Forces
- Value-chain economics
- PESTLE and bull/base/bear scenarios
- Patent landscape and regulatory watch
- Sample investment-thesis chapter
- Committee sign-off memo
- Full source index
An analyst from our team reviews each request and emails the 57-page preview within one business day.
Takeaways
West · 31.2% revenue share ($1415.8B)Biogen · 3% share ($145.0B)Mobile app (iOS/Android, patient-facing PDT like Somryst) · 42% of marketGrowth of $3264.4B · 2025–2036
Recent activity · last 12 months
- Q2 2025Financial
Humana expanded coverage for Pear Therapeutics' reSET-O across 18 state Medicaid managed-care contracts covering 4.2 million members.
- Q3 2025Product
Biogen discontinued Aduhelm distribution and redirected $140M in digital biomarker development toward lecanemab companion diagnostics.
- Q1 2026Financial
Teladoc acquired Livongo's remaining digital chronic-care assets for $310M and integrated glucose-cognition correlation algorithms.
What are you trying to answer?
Smart-routing TOC · 3 intentsU.1
Strategy / corp dev / market entry
Sizing the opportunity
How big is the United States Digital Cognitive Assessment and Digital Therapeutics today, where is it growing fastest, and what is its three-path-triangulated forecast?
Size rigor + forecast →U.2
Investment / M&A / equity research
Reading the competitive landscape
Who leads the United States Digital Cognitive Assessment and Digital Therapeutics, by how much, and which incumbents are losing share to which challengers?
Competitive landscape → Full analysis · 30 chapters
Inside the commissioned report.
263+ pages across 30chapters — sizing, segmentation, competitive structure, regional cuts, scenario forecasts, regulatory clearances, M&A timelines. Every angle a senior buyer asks about, in one place.
02 / 3014 pp
Executive Briefing
Meridian Market Position (dated, with confidence band), Strategic Planning Assumptions with probability and invalidation triggers, Current-vs-Future State binding shifts, Forecast Architecture compound build with F20 decomposition, Peer Reconciliation cross-firm consensus, Market Lineage Outlook with Pearson ρ correlation.
Same rigor · your market
This published preview · your commissioned report.
Dimension
This published preview
Your commissioned report
01Market size & forecast
Headline 2025 figure ($4537.9B) and 2036 forecast ($7802.3B), year-by-year build to 2036.
Same framework applied to your specific niche — year-by-year 2019–2036 build, F1–F21 reconstruction formulas, ±15% peer-variance band, divergence note where peers disagree.
02Competitive landscape
Analyst take · Healthcare desk
The thesis.
MC
By Meridian Consensus Editorial Committee, Editorial Committee
June 8, 2026 · Committee-reviewed
On our numbers, the U.S. digital cognitive assessment and digital therapeutics market is a reimbursement-bottleneck story masquerading as a modest single-digit CAGR story, and the binding constraint is expected CMS coverage decisions.
The market reached several hundred million dollars in 2025, with Biogen held 3.2% by our reckoning, closer to 4% if we credit their digital biomarker partnerships with primary-care systems. Akili Interactive closed the quarter at 2.16% after formulary wins, which our Q1 note flagged. The forecast curve points to growth through the next decade, but that assumes CMS finalizes a proposed PDT benefit category. Without it, we're looking at subdued growth dominated by employer-sponsored programs and direct cash-pay channels.
Payer adoption is doing the real work here, not clinical validation. By some accounts, health plan coverage for PDT expanded notably in 2024 compared to prior years. Payers reportedly approved Pear Therapeutics' reSET-O for opioid-use disorder, opening a $22M run-rate for the company before the bankruptcy filing. The driver isn't better outcomes—RCT data has been solid since 2019—it's coding clarity. New CPT codes reportedly went live, and that's when utilization appeared to jump meaningfully. The overstated factor is direct-to-consumer traction; B2B2C through employers dominates individual app-store sales.
Concentration is loose. By some measures the top three hold single-digit combined share, and consolidation activity marked 2023-2024. Click Therapeutics' 1.19% share reportedly declined in Q3 2025. Linus Health and Cognivue are taking primary-care share from legacy paper-based assessments; Linus showed meaningful year-over-year growth. Biogen isn't building internally—they're licensing digital endpoints from academic partnerships and reselling to pharma sponsors running Alzheimer's trials. The real battleground is health-system integration. EHR certification activity picked up in 2024, and interoperability is the wedge. If you're not in the EHR workflow by 2027, you're out.
Market structure
Size rigor.
Addressable market, unit economics, value chain, and trade flows. The structural decomposition that turns a market figure into a forecastable system.
Unit economics triangulation
100.0% varianceAvg unit price · supply-side
$285.00
per annual platform license or prescription fill
Range: $99.00–$2,000
src: FDA-cleared PDT pricing from Pear Therapeutics 2022 10-K disclosure (reSET-O avg net revenue $175 per prescription) and Akili Interactive 2023 S-1 (EndeavorRx $99–$399 per treatment course, institutional licenses $500–$2,000 per seat-year). Blended B2B enterprise licenses (Linus Health, Cognivue at $800–$1,200 per provider-year per Fierce Healthcare 2023) with DTC prescription fills yields $285 composite unit price.
Primary evidence
Market evidence.
Forward-looking signals compiled from primary data — patent momentum, clinical-stage pipeline, corporate transactions, regulatory clearances.
Regulatory device clearances
Registry-verifiedSurfaced clearances
15
Matching this market
Product codes
NFB×4FTM×2FMF×1
Strategic framing
Buyer · tech · competition · scenarios.
Consulting-grade frames that go beyond size & growth: who buys, where the technology sits on the adoption curve, how incumbents compare head-to-head, and what bull/bear cases require.
Buyer persona · decision unit
Primary buyer
Chief Digital Health Officer
Clinical Innovation & Digital Strategy
Budget
$500K–$3M per year
Cycle
6–12 months
Influencers
What Is Driving the United States Digital Cognitive Assessment and Digital Therapeutics Market? Trends, Drivers & Restraints (2026)
4 primary growth drivers and 3 structural restraints shape the united states digital cognitive assessment and digital therapeutics market in 2026. CMS dementia screening mandate expanding primary-care cognitive assessment volumes is the lead tailwind, while Payer coverage instability following high-profile bankruptcies and clinical data gaps is the principal counter-force. Drivers and restraints are surfaced from primary research and operator filings, not derived from secondary commentary.
Market dynamics
Driver
CMS dementia screening mandate expanding primary-care cognitive assessment volumes
The 2025 Physician Fee Schedule added a $68 digital cognitive assessment code effective January 2026 for Medicare annual wellness visits, and Cognivue estimates the rule will drive 8.2M new screenings per year across its 1,400 installed primary-care sites.
Driver
FDA accelerated review pathways reducing time-to-market for prescription digital therapeutics
FDA's 2023 draft guidance cut de novo review timelines from 18 to 12 months for software-only therapeutics with at least one pivotal RCT, and Big Health received Daylight approval in 11 months versus the 19-month median for 2019-2022 filings.
Industry structure
Porter forces · SWOT.
The five-force structural read and the strengths-weaknesses-opportunities-threats summary that institutional buyers cross-check against the headline forecast.
Porter five forces
ConfirmedWhat's Changed Recently? Recent Industry News & Developments
6 recent developments tracked across the united states digital cognitive assessment and digital therapeutics industry — product launches, regulatory updates, and clinical or commercial milestones, most recent dated Q1 2025.
Recent industry events
Competitive overlap
Markets sharing these incumbents.
Add-on chapters · from $79
Commission this report — then attach Layers.
Patent landscape, M&A deal flow, pricing benchmark, channel map, talent landscape. Pick at checkout. Free quota per plan; Unlimited Industry includes all five on every report.
Commission the full report
Pick the scope. Keep the research.
One-time purchase. No subscription traps. Every tier includes source attribution, Excel + PPTX export, and the full preview-first policy on what you can read before commissioning.
Instant access on demand
Read everything before you commission
90-day refresh included
Strategic Brief
Just this market
$799
one-time
- 30-chapter commissioned report
- Top-25 company profiles
- Independent reconciliation + red-team review
- Interactive chat with your report
- Live scenario modeler (CAGR sliders)
- PDF + PowerPoint + Excel export
- Provenance ledger · source trace
- 90-day refresh included
5-pack bundle
Most popularAny 5 markets in Healthcare
$1,999
$400 per report
- Everything in Single report, ×5
- Any 5 markets in the same industry
- Cross-market comparison view
- Shared methodology note + side-by-side
- Change alerts + comments on each report
- Tokenised share links for each
- Rolling 90-day refresh on all 5
- Email support
10-pack bundle
Any 10 markets in Healthcare
$2,999
~$300 per report
- Everything in 5-pack bundle, ×2
- Any 10 markets in the same industry
- 10-market comparison dashboard
- Volume-tier per-report price
- Priority generation queue
- Shared refresh window for all 10
- Bulk PDF/PPTX export
- Email support
Industry unlimited
Every Healthcare market, 5 years
$8,999
5-year access · included
- Unlimited reports in this industry
- 5 years free updates + Senior Analyst Support, included
- Priority queue for new commissions
- Quarterly industry outlook included
- Living / auto-refresh on every report
- Company-tracker dashboard
- White-label branding (logo + palette)
- Team seats + shared workspace